annb0t
Top 20
MELBOURNE, Australia, June 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118). (PRNewsfoto/Telix Pharmaceuticals Limited)
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical...
>>> Read more: New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical...
>>> Read more: New ZIRCON Phase III Data Presented at SNMMI: Potential Utility of TLX250-CDx in Staging and Monitoring ccRCC
